Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Apr;96(1):146–151. doi: 10.1111/j.1365-2249.1994.tb06244.x

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.

P Ettehadi 1, M W Greaves 1, D Wallach 1, D Aderka 1, R D Camp 1
PMCID: PMC1534536  PMID: 8149659

Abstract

Lesions of the common inflammatory skin disease psoriasis are characterized by epidermal hyperproliferation, leucocyte adhesion molecule expression and leucocyte infiltration. The local release of proinflammatory cytokines, such as TNF-alpha, may play an important role in the induction of these events. We have, therefore, analysed aqueous extracts of lesional and uninvolved (clinically normal) stratum corneum for the presence of TNF-alpha immunoreactivity and biological activity. TNF-alpha immunoreactivity and bioactivity were consistently higher in lesional compared with uninvolved samples. By using an anti-TNF-alpha neutralizing antibody it was demonstrated that the biological activity measured was due to the presence of TNF-alpha alone. Concentrations of soluble TNF receptors (p55 and p75) were also higher in lesional stratum corneum extracts, with the p55 form predominating. The plasma of psoriatic patients was also found to contain elevated concentrations of soluble p55 compared with normal controls. These results confirm the presence of immunoreactive TNF-alpha and, for the first time, conclusively demonstrate TNF-alpha biological activity and quantifiable concentrations of soluble TNF receptors (p55 and p75) in lesional psoriatic samples. TNF-alpha recovery from stratum corneum probably reflects synthesis in deeper, viable layers, where it is likely to exert its biological effects. Local and systemic release of soluble TNF receptors, in particular p55, may serve to regulate the effects of TNF-alpha in psoriasis.

Full text

PDF
146

Images in this article

149Fig. 3
on p.149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Englemann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed] [Google Scholar]
  2. Adolf G. R., Frühbeis B. Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. Cytokine. 1992 May;4(3):180–184. doi: 10.1016/1043-4666(92)90053-t. [DOI] [PubMed] [Google Scholar]
  3. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990 Aug;4(11):2860–2867. [PubMed] [Google Scholar]
  4. Barker J. N., MacDonald D. M. Cutaneous lymphocyte trafficking in the inflammatory dermatoses. Br J Dermatol. 1992 Mar;126(3):211–215. doi: 10.1111/j.1365-2133.1992.tb00647.x. [DOI] [PubMed] [Google Scholar]
  5. Barker J. N., Nickoloff B. J. Leukocyte-endothelium interactions in cutaneous inflammatory processes. Springer Semin Immunopathol. 1992;13(3-4):355–367. doi: 10.1007/BF00200534. [DOI] [PubMed] [Google Scholar]
  6. Brockhaus M., Schoenfeld H. J., Schlaeger E. J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3127–3131. doi: 10.1073/pnas.87.8.3127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bruynzeel I., Nickoloff B. J., van der Raaij E. M., Boorsma D. M., Stoof T. J., Willemze R. Induction of ICAM-1 expression by epidermal keratinocytes via a paracrine pathway possibly involving dermal dendritic cells. Arch Dermatol Res. 1992;284(4):250–252. doi: 10.1007/BF00375804. [DOI] [PubMed] [Google Scholar]
  8. Colditz I. G., Watson D. L. The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. Immunology. 1992 Jun;76(2):272–278. [PMC free article] [PubMed] [Google Scholar]
  9. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989 Jul 15;264(20):11974–11980. [PubMed] [Google Scholar]
  10. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  11. Gearing A. J., Fincham N. J., Bird C. R., Wadhwa M., Meager A., Cartwright J. E., Camp R. D. Cytokines in skin lesions of psoriasis. Cytokine. 1990 Jan;2(1):68–75. doi: 10.1016/1043-4666(90)90045-u. [DOI] [PubMed] [Google Scholar]
  12. Griffiths C. E., Voorhees J. J., Nickoloff B. J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol. 1989 Apr;20(4):617–629. doi: 10.1016/s0190-9622(89)70073-6. [DOI] [PubMed] [Google Scholar]
  13. Groves R. W., Allen M. H., Barker J. N., Haskard D. O., MacDonald D. M. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol. 1991 Feb;124(2):117–123. doi: 10.1111/j.1365-2133.1991.tb00419.x. [DOI] [PubMed] [Google Scholar]
  14. Gullberg U., Lantz M., Lindvall L., Olsson I., Himmler A. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. Eur J Cell Biol. 1992 Aug;58(2):307–312. [PubMed] [Google Scholar]
  15. Hopkins S. J., Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol. 1988 Jul;73(1):88–92. [PMC free article] [PubMed] [Google Scholar]
  16. Jones E. Y., Stuart D. I., Walker N. P. Structure of tumour necrosis factor. Nature. 1989 Mar 16;338(6212):225–228. doi: 10.1038/338225a0. [DOI] [PubMed] [Google Scholar]
  17. Meager A., Parti S., Leung H., Peil E., Mahon B. Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma. 1987 Jun;6(3):305–311. doi: 10.1089/hyb.1987.6.305. [DOI] [PubMed] [Google Scholar]
  18. Ming W. J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987 Mar 1;138(5):1469–1474. [PubMed] [Google Scholar]
  19. Nickoloff B. J., Karabin G. D., Barker J. N., Griffiths C. E., Sarma V., Mitra R. S., Elder J. T., Kunkel S. L., Dixit V. M. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991 Jan;138(1):129–140. [PMC free article] [PubMed] [Google Scholar]
  20. Smith R. A., Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem. 1987 May 25;262(15):6951–6954. [PubMed] [Google Scholar]
  21. Takematsu H., Ohta H., Tagami H. Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis. Arch Dermatol Res. 1989;281(6):398–400. doi: 10.1007/BF00455324. [DOI] [PubMed] [Google Scholar]
  22. Wakefield P. E., James W. D., Samlaska C. P., Meltzer M. S. Tumor necrosis factor. J Am Acad Dermatol. 1991 May;24(5 Pt 1):675–685. doi: 10.1016/0190-9622(91)70102-8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES